Gritstone Oncology, Inc. (GRTS): Price and Financial Metrics
Gritstone Oncology, Inc. (GRTS)
Today's Latest Price: $6.33 USD
0.36 (-5.38%)
Updated Jul 7 6:55pm
Add GRTS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
GRTS Stock Summary
- With a one year PEG ratio of 0.27, Gritstone Oncology Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 5.07% of US stocks.
- GRTS's went public 1.78 years ago, making it older than just 3.27% of listed US stocks we're tracking.
- GRTS's price/sales ratio is 58.25; that's higher than the P/S ratio of 96.29% of US stocks.
- Stocks that are quantitatively similar to GRTS, based on their financial statements, market capitalization, and price volatility, are AFMD, SPRO, MORF, UMRX, and CLDX.
- Visit GRTS's SEC page to see the company's official filings. To visit the company's web site, go to gritstoneoncology.com.
GRTS Daily Price Range
GRTS 52-Week Price Range
GRTS Stock Price Chart Technical Analysis Charts
GRTS Price/Volume Stats
| Current price | $6.33 | 52-week high | $12.96 |
| Prev. close | $6.69 | 52-week low | $5.42 |
| Day low | $6.29 | Volume | 725,500 |
| Day high | $6.76 | Avg. volume | 203,560 |
| 50-day MA | $6.67 | Dividend yield | N/A |
| 200-day MA | $7.84 | Market Cap | 235.89M |
Gritstone Oncology, Inc. (GRTS) Company Bio
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing personalized cancer immunotherapies for various cancer types in the United States. It is developing GRANITE-001, a personalized immunotherapy product for cancer patients; and SLATE-001 for patients with common tumor neoantigens. The company was founded in 2015 and is based in Emeryville, California.
Loading social stream, please wait...